safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
Published 1 year ago • 725 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
4:31
ropeginterferon alfa-2b in patients with pre-fibrotic primary mf & dipss low/intermediate-1 risk mf
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
0:56
rop-et: a phase iii non-randomized study of ropeginterferon alfa-2b in patients with et
-
1:22
safety and efficacy of cesnicabtagene autoleucel (ari0002h) for r/r mm
-
3:03
an insight into the momentum trial: safety and efficacy of momelotinib for the treatment of mf
-
3:02
pilot study of ropeginterferon in early myelofibrosis
-
4:10
the management of prefibrotic myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
24:20
introduction to haemostasis
-
22:52
haematological emergencies
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
2:41
safety and efficacy of actaly-cel™ in r/r pediatric b-all
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
2:16
long-term safety of momelotinib for myelofibrosis
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
3:52
a phase ii study evaluating the safety and efficacy of olutasidenib in patients with r/r midh1 aml
-
2:14
risk-adapted treatment of et & pv
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
4:48
an insight into the management of cytopenias in mf